Ekman P
Scand J Urol Nephrol. 1982;16(1):37-43. doi: 10.3109/00365598209179638.
The outcome for 84 patients in different stages of non-seminomatous germinal cell tumours of the testicle and treated with Mithramycin as a single agent has been evaluated. The survival rate in patients with advanced disease was lower than that obtained by more aggressive chemotherapy and, therefore, in these stages Mithramycin therapy is not recommended. On the other hand, the survival rate in patients with low-stage disease was superior to that in other series of patients subjected to bilateral lymphadenectomy without subsequent adjuvant chemotherapy. In the present study a unilateral gland dissection with preservation of a normal sexual function was performed in the vast majority of patients. Single-drug chemotherapy should preferably be used only as adjuvant treatment in low-stage non-seminomatous germinal cell testicular tumours.
对84例处于不同阶段的睾丸非精原性生殖细胞肿瘤患者使用光辉霉素单药治疗的结果进行了评估。晚期疾病患者的生存率低于采用更积极化疗所获得的生存率，因此，在这些阶段不推荐使用光辉霉素治疗。另一方面，低期疾病患者的生存率高于其他系列未进行后续辅助化疗而行双侧淋巴结清扫术的患者。在本研究中，绝大多数患者接受了保留正常性功能的单侧腺体切除术。单药化疗最好仅用作低期非精原性生殖细胞睾丸肿瘤的辅助治疗。
